Item 1.01 Entry into a Material Definitive Agreement.

On June 2, 2020, Intellia Therapeutics, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Leerink LLC, as representatives of the several underwriters listed on Schedule A thereto (the "Underwriters"), related to a public offering (the "Offering") of 5,479,453 shares (the "Shares") of common stock of the Company, par value $0.0001 per share (the "Common Stock") at a price to the public of $18.25 per share. In addition, the Company granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 821,917 shares. The Company estimates that the net proceeds from the Offering will be approximately $93.5 million (or approximately $107.6 million if the underwriters exercise in full their option to purchase additional shares) after deducting the underwriting discount and commissions and estimated offering expenses. The Offering is expected to close on June 5, 2020, subject to customary closing conditions.

The Company made certain customary representations, warranties and covenants concerning the Company and the registration statement in the Underwriting Agreement and also agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). The Offering is made pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-227814), including the prospectus dated June 6, 2019, as supplemented by a prospectus supplement dated June 2, 2020. This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any of the shares of Common Stock.

The foregoing description of certain terms of the Underwriting Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Underwriting Agreement, which is attached as Exhibit 1.1 hereto and is incorporated by reference herein. A copy of the opinion of Goodwin Procter LLP, relating to the legality of the issuance and sale of the Shares, is filed as Exhibit 5.1 hereto and is incorporated by reference herein.

Item 8.01 Other Events.

On June 1, 2020, the Company issued a press release announcing the Offering and on June 2, 2020, the Company issued a press release announcing that it had priced the Offering. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




  (d) Exhibits.


 Exhibit
   No.                                       Description

    1.1            Underwriting Agreement, dated as of June 2, 2020, by and among the
                 Company and Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Leerink
                 LLC, as representatives of the several underwriters listed on
                 Schedule A thereto

    5.1            Opinion of Goodwin Procter LLP

   23.1            Consent of Goodwin Procter LLP (included in Exhibit 5.1)

   99.1            Press release announcing the launch of the underwritten offering,
                 dated June 1, 2020

   99.2            Press release announcing the pricing of the underwritten offering,
                 dated June 2, 2020

   104           104 Cover Page Interactive Data File (embedded within the Inline
                 XBRL document).

Forward Looking Statements

This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Intellia's anticipated public offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed

--------------------------------------------------------------------------------

or implied by any forward-looking statements, including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Intellia's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the U.S, Securities and Exchange Commission ("SEC"), as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. Any forward-looking statements represent Intellia's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses